Human amniotic membrane intra-articular injection prevents cartilage damage in an osteoarthritis model


1Pathology Service; 2Orthopedics and Traumatology Service; 3Obstetrics and Gynecology Service; 4Transplants Service, Hospital Universitario ‘Dr. José E. González’; 5Department of Histology, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, NL 64460; 6Top Health, SAPI de CV, Zapopan, JAL 45070, Mexico

Received March 8, 2017; Accepted August 9, 2018

DOI: 10.3892/etm.2018.6924

Abstract. Osteoarthritis (OA) is a degenerative joint disease that affects the soft tissues and bones of involved articulations as a result of deregulation between synthesis and extracellular matrix degradation in articular cartilage. The present study evaluated the effect of intra-articular injection of human amniotic membrane (AM) as a treatment in an OA animal model in the knee. Chemical OA was developed in the knees of New Zealand rabbits. Once OA was established, the right knees only were treated with an intra-articular injection of human AM, with the left knees considered as a negative control group. The evaluation was performed at 3 and 6 weeks post-treatment. At 3 weeks post-injection, the cartilage exhibited fibrillation, erosion, cracks and cell clusters in the negative control group, but not in the treated group (P=0.028). At 6 weeks post-injection, the left knees exhibited hypertrophy, cracks, cell clusters, decreased matrix staining and structure loss. However, the right knees exhibited cell clusters without evidence of disruption in cartilage integrity (P=0.015). These results suggested that the intra-articular injection of human AM delays histological changes of cartilage in OA.

Introduction

Osteoarthritis (OA) is a multifactorial, degenerative and incapacitating disease that affects the soft tissues and bones of the involved articulations, causing pain and decreased function due to differences between the rate of synthesis and extracellular matrix degradation of articular cartilage (1-3).

Correspondence to: Dr J. Lara-Arias, Orthopedics and Traumatology Service, Hospital Universitario ‘Dr. José E. González’, Universidad Autónoma de Nuevo León, 104-C Av. Madero y Gonzalitos s/n, Monterrey, NL 64460, Mexico. E-mail: jorgelara77@gmail.com

Key words: osteoarthritis, cartilage, osteoarthritis, articular cartilage, amniotic membrane

Nonsteroidal anti-inflammatory drugs and intra-articular steroid injections are commonly indicated as a first choice treatment in OA. Together with physical exercise and corporal weight control, the purpose of this treatment is to relieve pain and to improve articular function; however, it is not always effective. Although the intra-articular injection of hyaluronic acid has been approved as a knee OA treatment in patients for which non-drug treatment and simple analgesics have been unsuccessful, this treatment is palliative but not therapeutic (4).

The amniotic membrane (AM) is the innermost fetal membrane, usually discarded following birth as part of the placenta. The membrane itself and stem cells isolated from it have shown potential for applications in the regenerative medicine field, due to bacteriostatic and anti-angiogenic properties. It also has been shown that AM reduces pain, regulates the inflammatory process, and improves wound healing and epithelialization (5-8); it also exhibits low or no immunogenicity and acts as a physical barrier in the case of an exposed wound (9,10). In clinical trials, complete AM has been evaluated for the treatment of skin burns (11), as a scaffold biomaterial in the reconstruction of the ocular surface (12), in head and neck surgery (13), and to prevent tissue adhesion in abdominal, head and pelvic surgery (14). Acellular AM has been evaluated in articular cartilage and tendon defects (15) and also in peripheral nerves (16).

Morphologically, AM is a thin and flexible membrane comprising a monolayer of epithelial cells aligned on a basal membrane, where the underlying stroma contains mesenchymal cells (17). These cells have the ability to differentiate into several lineages, including adipogenic, osteogenic, chondrogenic, hepatic, neurogenic and cardiomyogenic tissue (18-23). Amniotic cells are immunomodulatory in vitro (23), and the AM and allogeneic amniotic cells have been applied in clinical trials without evidence of immunologic rejection (10). The osteogenic capability of this membrane, and the fact it can act as a stimulator in repairing musculoskeletal injuries has been reported (24).

The aim of the present study was to analyze the histological changes produced by lyophilized and pulverized human AM, administered as a treatment in an OA model of the knee developed in rabbits.
Materials and methods

Study type and ethics. The present study was an experimental, cross-sectional, comparative, prospective, simple blind study. The protocol was submitted to the Institutional Ethics and Research Committee of Universidad Autónoma de Nuevo León (Monterrey, Mexico) and approved (approval no. OR15-015).

AM isolation and processing. The placenta were obtained from healthy donors who were scheduled to have cesarean surgery in the obstetrics department of the Hospital General de Occidente (Zapopan, Mexico) from May 2017 to August 2017. The placenta were supplied by Top Health (Zapopan, Mexico) who provided proof of informed consent of the donors. Following separating of the placenta from the placental button, the chorionic membrane was then carefully separated. To decellularize the AM, it was washed with 15% NaCl and gently mixed in NaOH 0.01 N until brown in color. NaOH was neutralized by adding ascorbic acid (1N). Hydrogen peroxide solution and gentle mixing were used to obtain a white color membrane, followed which dehydration with 96% ethanol was performed. The membrane was placed to be dried for 24 h at room temperature in a ventilated area. The dried membrane was pulverized, and a screening was performed to determine the particle size. The membrane was lyophilized and irradiated with gamma rays of 25 kGy prior to use in animals.

Chemical AO model. In the present study, six adult male New Zealand rabbits aged ~3 months old and with an average weight of 2.5 kg were obtained from the Animal Production Unit of the Facultad de Agronomía (Escobedi, Mexico). The experimental animals were anesthetized with an intramuscular injection of 1.9 mg/kg xylazine and 46 mg/kg ketamine. Intra-articular injections of 250 μl of collagenase type II (Clostridium histolyticum type II, active enzyme 425 U/mg, Thermo Fisher Scientific, Inc., Waltham, MA, USA) were performed at days 0 and 4 (25). The rabbits were housed in individual cages at a temperature of 21˚C and a relative humidity of 55% with a 12 h light/dark cycle and ad libitum access to food and water.

Intra-articular infiltration of the AM. Once the OA model was established in both knees of all rabbits, the animals were divided into two observation groups, with three animals in each group. Each rabbit underwent an intra-articular infiltration in the right knee of the lyophilized human AM (0.040 mg/0.200 ml) and saline solution (0.6 ml) in the left knee (control group). The animals were sacrificed with an overdose of xylazine and ketamine IV at 3 and 6 weeks (Group 1 and 2, respectively). The knees were obtained from each rabbit and placed in formaldehyde solution for preservation. All previously identified samples were sent for histological examination.

Morphological and histological analysis. The macroscopic morphological analysis was performed using the scale published by Yoshioka et al (26) in which the grades are as follows: Grade 1, intact articular surface; grade 2, minimal fibrillation; grade 3, evident fibrillation; grade 4, erosion with bone exposure (Table I).

Each knee sample was fixed and decalcified prior to being embedded in paraffin blocks. From these, 4-μm sagittal sections were made and stained with hematoxylin and eosin (H&E) for structure, cellularity and ‘tidemark’ integrity evaluation. Masson's trichrome staining was used for the extracellular matrix evaluation. Histopathological assessment of cartilage damage was performed following Mankin's scale (27) (Table I). This scale assigns a histological score by adding the corresponding values to the changes in the cartilage structure, cellularity, matrix staining and in the ‘tidemark’ or basophilic limiting line. In this way, normal cartilage corresponds to 0 points and the most severe cartilage affection corresponds to 14 points. The morphologic and histopathologic evaluations were performed by independent observers who did not know which group they assessed. Slides were observed using a Nikon fluorescent microscope (E600; Nikon Corporation, Tokyo, Japan).

Statistical analysis. The sample size calculation for animal models with α=0.05, β=0.08 (one-tailed) was six individuals per group. Calculating a sample size for comparison of related averages α=0.05, β=0.08 (two-tailed), taking a minimum difference of 2.5, it was seven individuals per group. The numerical variables were analyzed using one-way analysis of variance with Tukey's multiple comparisons post-hoc test to estimate the differences between groups.

Significance was determined at P≤0.05 was considered to indicate a statistically significant difference. Descriptive and inferential statistical analyses were performed using STATA-10-08 software (Stata Corporation, College Station, TX, USA).

Results

Human AM prevents macroscopic changes in the cartilage of OA model. In the left knees of group 1, cartilage fibrillation and color changes were observed on the joint surface compared with the right knees which showed a macroscopic apparently intact surface. However, small areas with poor fibrillation were observed in the right knees (Fig. 1A and B). Despite these data, a statistically significant difference (P=0.024) was found when Yoshioka’s scale scores of the left knees (3.15±0.73) and right knees (2.36±0.76) were compared.

In the left knees of group 2, subchondral bone was observed in regions of the femoral condyles and the tibial plateau (Fig. 1C and D). The left knees were assigned a score of 4.25±0.32 according to Yoshioka's scale evaluation, whereas the right knees were assigned a score of 1.29±0.49 (P=0.015; Table I).

Human AM protects from extracellular matrix destruction in the OA model. On examining the cartilage morphology in left knees of the group 1, increased fibers in the superficial regions of the femoral condyles and the tibial plateau (Fig. 1C and D). The left knees were assigned a score of 4.25±0.32 according to Yoshioka's scale evaluation, whereas the right knees were assigned a score of 1.29±0.49 (P=0.015; Table I).

When the cellularity and matrix staining were evaluated, the left knees exhibited more cell clusters and reduced staining in regions where joint surface fibrillation was detected. By contrast, the right knees exhibited fewer and isolated cell clusters, with no decrease or loss of staining density. Overall, a
significant statistical difference was observed when comparing the left and right knees of group 1 (P=0.028).

In group 2, the H&E (Fig. 2C and D) and Masson’s trichrome staining (Fig. 3A and B) showed cracks, loss of structure, recesses, erosion, and fibrillation in the left knee cartilage. Abundant cell clusters and decreased staining were observed on the surface and extracellular matrix. The right knees of group 2 exhibited an almost intact surface with minimal articular fibrillation, no cracks and no evident surface erosion (Figs. 2 and 3). A number of cell clusters were observed in isolated areas where the cartilage surface was not compromised. Normal staining was observed on the cartilage surface and extracellular matrix.

For groups 1 and 2, there was no evident ‘Tidemark’ injury and statistical differences were found on comparing the right and left knees for Mankin’s evaluation scale (Table I; P=0.028 and P=0.015).

**Discussion**

The AM has been investigated mainly for ophthalmologic applications, including regenerative medicine in the cornea (12). A number of studies investigating AM use in articular cartilage lesion regeneration have been reported and a chondroprotective effect with reduced proteoglycan loss, preventing damage progression of the extracellular matrix, were demonstrated (28). In a study investigating the injection of dehydrated human amnio/chorionic product, fewer defects and smaller lesion volumes were observed when compared with saline solution-injected control animals at day 21 post-injection; the study demonstrated cartilage destruction attenuation with increases in cartilage thickness and volume, and a decrease in total lesion area in animals injected with particulate AM (29). However, this previous study used a model in Lewis rats that underwent medial meniscal transection surgery to induce OA and did not perform histopathological analysis, which is considered to be the ‘gold standard’ for evaluating the potential therapeutics for OA. In the present study, a chemical OA model in rabbits was used and, as the joints of these animals are larger than the knees of rats, this may provide further support to the significance to the results.

In another study, in which a particulate AM and umbilical cord tissue in an OA model were used, their results were compared with EPIC-micro CT and histopathology to demonstrate a significant reduction in cartilage degeneration and

---

**Table I. Yoshioka’s scale for macroscopic evaluation and Mankin’s scale for histological evaluation.**

<table>
<thead>
<tr>
<th>Group</th>
<th>Time post-injection (weeks)</th>
<th>Left knee injury</th>
<th>Right knee injury+AM</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yoshioka’s scale</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>3</td>
<td>3.15±0.73</td>
<td>2.36±0.76</td>
<td>0.024</td>
</tr>
<tr>
<td>2</td>
<td>6</td>
<td>4.25±0.32</td>
<td>1.29±0.49</td>
<td>0.015</td>
</tr>
<tr>
<td>Mankin’s scale</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>3</td>
<td>4.33±0.67</td>
<td>2.44±0.21</td>
<td>0.028</td>
</tr>
<tr>
<td>2</td>
<td>6</td>
<td>6.54±0.43</td>
<td>1.87±0.73</td>
<td>0.015</td>
</tr>
</tbody>
</table>

AM, amniotic membrane.
calcified cartilage at week 1 post-injection, providing further evidence that AM assists in preventing and treating OA (30).

The present study demonstrated that pulverized AM injected intra-articularly improved histological features of OA cartilage in rabbit knees, decreased disease progression and delayed histological changes, including loss of extracellular matrix staining. This is possibly due to it being responsible for supplying growth factors, that allow adequate re-epithelialization and epithelial cell migration. The low or absent immunogenicity of AM represents an advantage that reduces complications. However, it remains necessary to obtain further scientific evidence prior to indicating that AM is safe for its use in humans as a treatment for OA of the knee. Therefore, a novel animal model of a higher level in the phylogenetic scale is required to investigate the efficacy and safety of the AM application.
Although the majority of the studies involving AM use animal models to reproduce OA disease, a number of studies have used AM for clinical trials in human volunteers. Vines et al (31) demonstrated the intraarticular injection feasibility of cryogenically preserved human amniotic suspension allografts for human patients suffering OA of the knee. Díaz-Prado et al (32) used human AM as a scaffold in human articular cartilage repair, and demonstrated that cryopreserved human AM can be used to support chondrocyte proliferation (32). Previous studies in tissue engineering have used cultured chondrocytes on the AM for use as a scaffold, and the results indicated the presence of collagen type II and an extraacellular matrix similar to hyaline cartilage (32,33). This fact may be due to the AM having a high content of transforming growth factor-β1, and this protein upregulates chondrogenic gene expression (34,35).

These results of the present study suggested that the treatment of early OA is feasible using an AM with different presentations, either fresh or cryopreserved. The present study used lyophilized, pulverized AM in saline solution as a vehicle for resuspension. This presentation is easy to handle and store, and reduces the infection risk as it is dried until resuspension in PRP. However, further investigations are required to determine the safety and efficacy of AM in clinical trials for the treatment of OA and other orthopedic problems, including ligament sprains, and fracture complications, including pseudoarthrosis, among others.

Acknowledgements

The present study was supported by The Orthopedics and Traumatology Service, Hospital Universitario ‘Dr. José E. González’, Universidad Autónoma de Nuevo León, and Top Health SAPI de CV.

Funding

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

IHAM analyzed and interpreted the data. AGMC established the animal model. VMPM performed the histological knee examination. VMPM participated in the design of the protocol for animal model development. CAAO examined the histological sections as a blind observer and contributed to the statistical analysis. FVC participated in the interpretation of results and the writing of the final manuscript. FVC was also responsible for processing amniotic membranes at the Bone and Tissue Bank of the Universidad Autónoma de Nuevo León prior to use in the study. AGL obtained knees following euthanasia and processed sections using histological techniques. EPR contributed to the experiments. JAOB participated in the construction of the Discussion section of the final manuscript and reviewing the English. JLA contributed to the design of the study, the reviewing of all procedures and the writing of the final manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The protocol was submitted to the Institutional Ethics and Research Committee of Universidad Autónoma de Nuevo León and approved (approval no. OR15-015). Informed consent was provided by the donors of placentas.

Patient consent for publication

Not applicable.

Competing interests

The authors confirm that they have no competing interests.

References